21182 ⎘
Medicinal preparations containing antigens or antibodies characterised by the route of administration; Mucosal route to the airways
METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#2VIRUS-LIKE PARTICLES FOR PREVENTING THE SPREADING AND LOWERING THE INFECTION RATE OF VIRUSES
#3COMPOSITIONS, KITS, AND METHODS OF IMMUNIZING AGAINST VIRAL INFECTIONS
#4FLAVIVIRUS IMMUNOGENS AND VACCINE COMPOSITIONS AND METHODS OF USING THE SAME
#5TREHALOSE-BASED SURFACTANTS
#6Larygotracheitis Virus (LT) Vector Vaccines for use with Avian Respiratory Pathogens
#7IMMUNOSTIMULATORY PREPARATION AND COSMETIC, FOOD, FEED ADDITIVE, AND QUASI-PHARMACEUTICAL PRODUCT CONTAINING THE IMMUNOSTIMULATORY PREPARATION
#8COMPOSITIONS AND METHODS RELATED TO EXTRACELLULAR VESICLE THERAPEUTIC DELIVERY PLATFORM
#9SURFACE CONJUGATION TO POLY(AMINE-CO-ESTER) NANOPARTICLES FOR TARGETING TO CELLS AND TISSUES
#10MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS
#11VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A TLR3 AGONIST
#12METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER
#13VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A TLR3 AGONIST
#14NANOSTRUCTURE-FORMING POLYPEPTIDES AND USES THEREOF
#15COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS
#16METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#17INTERFERON- INDUCING COMPLEXES AND RNA DUPLEXES AND METHODS OF USE
#18CARRIER FOR LOWERING THE INFECTION RATE OF BACTERIA
#19IBV VACCINE WITH HETEROLOGOUS DMV/1639 SPIKE PROTEIN
#20Methods of fabricating carriers for targeted delivery to a host
#21INFLUENZA VIRUS REPLICATION FOR VACCINE DEVELOPMENT
#22VHH ANTIBODIES AGAINST SARS-COV-2 VARIANTS
#23NOROVIRUS VACCINE AND METHODS OF USE
#24INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN
#25ALLERGY TREATMENT
#26COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS
#27IN-SITU AND REAL-TIME GENERATION AND ADMINISTRATION OF VIRAL VACCINES USING UV LIGHT INACTIVATION
#28Methods for Providing a Vaccine
#29EXTENDED-RANGE SPRAY APPLICATOR
#30Compositions And Methods Of MAIT Cell Activation
#31Carrier for targeted delivery to a host
#32Fluorocarbon-Linked Peptide Formulation
#33CANCER IMMUNOTHERAPY USING VIRUS PARTICLES
#34COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS
#35VACCINE COMPOSITIONS
#36THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIA
#37SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS
#38Methods of permeabilizing the blood brain barrier
#39ANTI-INFECTION AND ANTI-TUMOR MUCOSAL IMMUNE PREPARATION
#40Influenza virus replication for vaccine development
#41Virus-like particles for preventing the spreading and lowering the infection rate of viruses
#42Cancer immunotherapy using virus particles
#43MATERIALS AND METHODS FOR POLYMERIC ANTIBODY RECEPTOR TARGETING
#44PARTICLES FOR STIMULATING AN IMMUNE RESPONSE AGAINST VIRAL INFECTIONS
#45Virus-like particles for preventing the spreading and lowering the infection rate of viruses
#46Composition and method for spray drying an adjuvant vaccine emulsion
#47Method and system for protecting monarch butterflies from pesticides
#48IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS
#49Pan-antiallergy vaccine
#50Composition and method of mRNA vaccines against novel coronavirus infection
#51BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
#52Compositions and methods of treating sarcoma lung metastasis
#53Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#54DRY PHARMACEUTICAL COMPOSITION FOR INHALATION
#55Virus vaccination system and methods
#56Extended-range spray applicator
#57Method and system for protecting honey bees from pesticides
#58Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#59Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
#60Compositions and methods for inhibiting pathogen infection
#61Influenza virus replication for vaccine development
#62Cancer immunotherapy using virus particles
#63Tuberculosis vaccine, preparation method therefor, and use thereof
#64Fluorocarbon-linked peptide formulation
#65FORMULATION OF ANTIBODY BASED DRUGS FOR TREATING LUNG CANCER BY INHALATION
#66Method and system for protecting honey bees from pesticides
#67Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#68Methods and compositions for inducing protective immunity
#69VACCINE COMPOSITIONS
#70Compositions comprising an anti-C5 antibody
#71Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#72KLRG1 antagonist signaling therapy
#73Tobacco products
#74Method and system for protecting honey bees from fipronil pesticides
#75Compositions comprising an anti-C5 antibody
#76POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#77Compositions and methods for inhibiting pathogen infection
#78Compositions and methods of treating sarcoma lung metastasis
#79Genetically engineered swine influenza virus and uses thereof
#80Anti-infection and anti-tumor mucosal immune preparation
#81Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
#82ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
#83Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
#84Nanoparticle based vaccine strategy against swine influenza virus
#85Methods and products for treating and/or delaying onset of dysplastic lesions
#86Cancer immunotherapy using virus particles
#87Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#88Swine influenza vaccine
#89EHV insertion site ORF70
#90Compositions comprising an anti-C5 antibody
#91COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY
#92Immunotherapy composition and use thereof
#93Recombinant swine influenza virus and uses thereof
#94Induction of mucosal tolerance to antigens
#95Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
#96Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
#97Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
#98Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
#99Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica
#100Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#101Monoclonal antibodies targeting neutralizing epitopes on H7 influenza viruses
#102Mucosal vaccine composition
#103Compositions Associated with and Methods of Managing Neutrophil Movement
#104Efficient mucosal vaccination mediated by the neonatal Fc receptor
#105Immunotherapy composition and use thereof
#106Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
#107Fluorocarbon-linked peptide formulation
#108Conditionally replication deficient herpes virus and use thereof in vaccines
#109Vaccination against
#110Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
#111Inhalable vaccine compositions and methods
#112Genetically engineered swine influenza virus and uses thereof
#113Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
#114Induction of mucosal tolerance to antigens
#115Induction of mucosal tolerance to antigens
#116Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
#117High concentration antibody formulations
#118Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#119Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#120Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
#121Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#122Genetically engineered swine influenza virus and uses thereof
#123Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
#124High concentration formulations of anti-C5 antibodies
#125Efficient mucosal vaccination mediated by the neonatal Fc receptor
#126Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
#127POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#128METHOD TO INHIBIT AIRWAY HYPERRESPONSIVENESS USING AEROSOLIZED T CELL RECEPTOR ANTIBODIES
#129SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN
#130PRODUCTION OF ATTENUATED NEGATIVE STRANDED RNA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
#131Dry Powder Formulations, Vaccines and Methods
#132RECOMBINANT PARAINFLUENZA VIRUS VACCINE COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM RESPIRATORY SYNCYTIAL VIRUS
#133Infectious bronchitis vaccines derived from IB-QX-like vaccine strains
#134Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells
#135CELL RECEPTOR BLOCKER FOR PREVENTING AND TREATING AVIAN INFLUENZA AND OTHER DISEASES CAUSED BY VIRUSES
#136IMMUNIZATION OF AVIANS BY MUCOSAL ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES
#137POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#138Live, attenuated respiratory syncytial virus
#139DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION
#140Stabilisation of Viral Microparticles
#141Avian influenza virus live attenuated vaccine and uses thereof
#142Use of anti-cancer cell composition for treatment of head and neck cancer, which is intended to be administered to nutrient artery of tumor
#143ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
#144POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTSMETHODS FOR
#145AEROSOLIZED GENETIC VACCINES AND METHODS OF USE
#146ALLERGY VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION
#147Polypeptides, antibody variable domains and antagonists
#148Antibody molecules having binding specificity for human IL-13
#149Polypeptides, antibody variable domains and antagonists methods for
#150POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#151METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES
#152POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#153Recombinant baculovirus vaccine
#154Method of inducing immune tolerance to type I diabetes
#155Method of elicting or inducing an immune response
#156Methods of producing microparticles
#157METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN COUNT CYCLES
#158POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#159Induction of mucosal tolerance to antigens
#160PRODUCTION OF ATTENUATED NEGATIVE STRANDED RNA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
#161Anti-IL-13 antibody formulations and uses thereof
#162Combination vaccine for poultry
#163Compositions and methods for transepithelial molecular transport
#164DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION
#165Genetically engineered swine influenza virus and uses thereof
#166Compositions and Methods for Stimulation of Lung Innate Immunity
#167Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
#168Pharmaceutical Aerosol Compositions
#169Feline influenza vaccine and method of use
#170Inhibition of factor B, the alternative complement pathway and methods related thereto
#171Inhibition of factor B, the alternative complement pathway and methods related thereto
#172Vaccine Formulated For Administration To Mucosa Of The Lungs
#173Infectious bronchitis virus vaccine
#174Intranasal or inhalational administration of virosomes
#175Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
#176Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
#177Stabilisation of viral microparticles
#178Gene expression vaccine
#179Mycoplasma gallisepticum formulation
#180Pharmaceutical aerosol composition
#181Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells
#182Vaccine delivery compositions and methods of use
#183Use of sendai virus as a human parainfluenza vaccine
#184Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
#185Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
#186Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
#187Nebulization of monoclonal antibodies for treating pulmonary diseases
#188Pulmonary malarial vaccine
#189Anti-factor B antibodies
#190Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
#191Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
#192Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
#193Method and compositions for treatment of insulin-dependant diabetes mellitus
#194Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
#195Method of obtaining protection against bystander allergen